<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="26b840cb-75b8-41f1-bcbb-287a0b2eca52"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>These highlights do not include all the information needed to use KETOROLAC TROMETHAMINE ophthalmic solution safely and effectively. See full prescribing information for KETOROLAC TROMETHAMINE ophthalmic solution.<br/> KETOROLAC TROMETHAMINE ophthalmic solution 0.5%<br/> Initial U.S. Approval: 1991</title>
   <effectiveTime value="20181024"/>
   <setId root="2c76b8f9-5385-4c98-aebb-bdca8613d24b"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="146974886" root="1.3.6.1.4.1.519.1"/>
            <name>Sun Pharmaceutical Industries, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="725959238" root="1.3.6.1.4.1.519.1"/>
                        <name>Sun Pharmaceutical Industries Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47335-219" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47335-220" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47335-221" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47335-219" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47335-220" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47335-221" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="70be49cd-5a04-4461-8b27-6623a725e208"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20181024"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47335-219" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ketorolac Tromethamine<suffix/>
                        </name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ketorolac Tromethamine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4EVE5946BQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>KETOROLAC TROMETHAMINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YZI5105V0L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>KETOROLAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9T1C662FKS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OCTOXYNOL-40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="47335-219-90" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180313"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA090017" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180313"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47335-220" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ketorolac Tromethamine<suffix/>
                        </name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ketorolac Tromethamine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4EVE5946BQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>KETOROLAC TROMETHAMINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YZI5105V0L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>KETOROLAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9T1C662FKS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OCTOXYNOL-40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="47335-220-90" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180313"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA090017" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180313"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47335-221" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ketorolac Tromethamine<suffix/>
                        </name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ketorolac Tromethamine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4EVE5946BQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>KETOROLAC TROMETHAMINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YZI5105V0L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>KETOROLAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9T1C662FKS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OCTOXYNOL-40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="47335-221-90" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180313"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA090017" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180313"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="c32124e1-54ff-476f-92cb-614df54fe643"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <br/>
                  <paragraph>Ketorolac tromethamine ophthalmic solution is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20181024"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ketorolac tromethamine ophthalmic solution is a nonsteroidal, anti-inflammatory indicated for: </paragraph>
                        <br/>
                        <list listType="unordered" styleCode="disc">
                           <item>The treatment of inflammation following cataract surgery. (<linkHtml href="#Section_1">1</linkHtml>) </item>
                           <item>The temporary relief of ocular itching due to seasonal allergic conjunctivitis. (<linkHtml href="#Section_1">1</linkHtml>)</item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="410c4445-05c7-41ec-a158-80cceb706f8b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20181024"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>One drop of ketorolac tromethamine ophthalmic solution should be applied to the affected eye(s) four times a day for relief of ocular itching due to seasonal allergic conjunctivitis. <br/>
                           <br/> For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of ketorolac tromethamine ophthalmic solution should be applied to the affected eye four times daily beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period. (<linkHtml href="#Section_2.1">2.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="4afb73a6-ead6-4ba7-a450-70b1d95a20d3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.1 Recommended Dosing</title>
                     <text>
                        <br/>
                        <paragraph>Patient Dosing <br/> The recommended dose of ketorolac tromethamine ophthalmic solution is one drop four times a day to the affected eye(s) for relief of ocular itching due to seasonal allergic conjunctivitis. <br/>
                           <br/> For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of ketorolac tromethamine ophthalmic solution should be applied to the affected eye four times daily beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="062fd433-7239-4a19-8351-1d021a82df57"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.2 Use with Other Topical Ophthalmic Medications</title>
                     <text>
                        <br/>
                        <paragraph>Ketorolac tromethamine ophthalmic solution has been safely administered in conjunction with other ophthalmic medications such as antibiotics, alpha-agonists, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="42735bba-9110-4aca-9c71-724a77473dbb"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Ketorolac tromethamine ophthalmic solution 0.5% is supplied sterile in white opaque LDPE dropper bottles with white opaque plug and sealed with gray pantone opaque pilfer-proof caps as follows: </paragraph>
                  <br/>
                  <list listType="unordered" styleCode="disc">
                     <item>5 mL size bottle filled with 3 mL of solution </item>
                     <item>5 mL size bottle filled with 5 mL of solution </item>
                     <item>10 mL size bottle filled with 10 mL of solution </item>
                  </list>
               </text>
               <effectiveTime value="20181024"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution containing 5 mg/mL ketorolac tromethamine. (<linkHtml href="#Section_3">3</linkHtml>) </paragraph>
                        <br/>
                        <list listType="unordered" styleCode="disc">
                           <item>5 mL size bottle filled with 3 mL of solution </item>
                           <item>5 mL size bottle filled with 5 mL of solution </item>
                           <item>10 mL size bottle filled with 10 mL of solution </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="1c932b0f-25d8-4f31-8ced-48dbb42cddba"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <br/>
                  <paragraph>Ketorolac tromethamine ophthalmic solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation.</paragraph>
               </text>
               <effectiveTime value="20181024"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to any component of this product. (<linkHtml href="#Section_4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="e5d09ee0-0361-4e46-8e2b-5ccc695fcc24"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20181024"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Delayed healing (<linkHtml href="#Section_5.1">5.1</linkHtml>) </item>
                           <item>Cross-sensitivity or hypersensitivity (<linkHtml href="#Section_5.2">5.2</linkHtml>) </item>
                           <item>Increased bleeding time due to interference with thrombocyte aggregation (<linkHtml href="#Section_5.3">5.3</linkHtml>) </item>
                           <item>Corneal effects including keratitis (<linkHtml href="#Section_5.4">5.4</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="82ca9038-5945-4bc0-9c68-b17b672b2a9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.1 Delayed Healing</title>
                     <text>
                        <paragraph>Topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="a2ee3ef6-04e2-494f-bb3c-7e8f7e056696"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.2 Cross-Sensitivity or Hypersensitivity</title>
                     <text>
                        <br/>
                        <paragraph>There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. There have been reports of bronchospasm or exacerbation of asthma associated with the use of ketorolac tromethamine ophthalmic solution in patients who have either a known hypersensitivity to aspirin/non-steroidal anti-inflammatory drugs or a past medical history of asthma. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="50d13a56-4f68-4dce-99ec-c001e55fb8e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.3 Increased Bleeding Time</title>
                     <text>
                        <br/>
                        <paragraph>With some NSAIDs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti- inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. <br/>
                           <br/> It is recommended that ketorolac tromethamine ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications, which may prolong bleeding time. </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="c2b13b5c-67a9-47f8-a214-b90d8282742c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.4 Corneal Effects</title>
                     <text>
                        <br/>
                        <paragraph>Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health. <br/>
                           <br/> Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. <br/>
                           <br/> Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events. </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="a6b7ef7b-adb4-44d8-a988-a06afd688187"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.5 Contact Lens Wear</title>
                     <text>
                        <paragraph>Ketorolac tromethamine ophthalmic solution should not be administered while wearing contact lenses.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="fa11646e-25de-4079-b651-43bcbad5624f"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20181024"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most frequent adverse reactions reported by up to 40% of patients participating in clinical trials have been transient stinging and burning on instillation. (<linkHtml href="#Section_6.1">6.1</linkHtml>) <br/> To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="384a825d-c313-4c55-96da-516e02ec5a44"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.1 Clinical Studies Experience</title>
                     <text>
                        <paragraph>Because cli nical studies are conducted under wi dely var ying  conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to t he rates in the clinical studies of another drug and  may not reflect t he rates observed in practice.</paragraph>
                        <br/>
                        <paragraph>The  most fr equent adverse react ions reported with the use of k etorolac tro meth a mine ophthal mic solutio ns have been tra nsient  stin gi ng and burni ng on instillation. These reactions were reported by up to 40% of patie nts partici pating in clinic al t rials.</paragraph>
                        <br/>
                        <paragraph>Other adverse reactions occurring approxi mately 1 to 10% of the ti me during tre at ment with ketor olac tr ometh a mine ophthal mic solutio ns inc luded aller gic reactions, corneal ede ma, iritis, ocular inflammation, ocular ir rit ati on, super fici al ker atitis,  and super ficial ocular in fectio ns.</paragraph>
                        <br/>
                        <paragraph>Other adverse reactions reported rarely with the use of ketorolac tro metha mine ophthal mic solutio ns included: c orneal infiltrates, corneal ulcer, eye dry ness, headac hes<content styleCode="bold">, </content>and visual disturbance (blurry vision).</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="831784d4-395f-409d-ba94-b3f1ba2309e7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postmarketing use of ketorolac tromethamine ophthalmic solution 0.5% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical ketorolac tromethamine ophthalmic solution 0.5% or a combination of these factors, include bronchospasm or exacerbation of asthma, corneal erosion, corneal perforation, corneal thinning, and epithelial breakdown <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>, <linkHtml href="#Section_5.4">5.4</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="1188a54f-62b4-48ae-8d2f-d5a8a15c22d8"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20181024"/>
               <component>
                  <section ID="Section_8.1">
                     <id root="c9fa9cc0-e0f6-44bb-819b-c2a476de3acb"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Teratogenic Effects.  P regnancy Category C</content>
                        </paragraph>
                        <paragraph>Pregnancy Category C: Ketorolac tr o metha min e, ad ministered during organogenesis, was not teratogenic in rabbits and rats at oral doses of 3.6  mg/kg/day and 10  mg/ kg/day, respectively. These doses are approxi mately 100 ti mes and 250 ti mes higher respectively than the  max i m um recom mended hu man topical op hthal mic daily  d ose of 2  mg (5  mg / mL x 0.05  mL/drop, x 4  drops x 2 eyes) to affected eyes on a  mg/kg basis. Additionally, when ad ministered to rats after Day 17 of  gestation at oral doses up to 1.5  mg/ k g/day (approxi mately 40 ti mes the typical hu man topical ophthal mic daily dose), ketorolac tro me tha mine resulted in dystocia and increased pup mortality.  There are no adequate a nd well-controlled studies in pregnant w o men.  Keto ro lac t ro met ham ine op htha lm ic  so lut i on should be used during pregnancy only if the potential bene fit j usti fies the p otential risk  to the  fetus.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Nonterato genic Effect s: </content>Because of the known effects of prostaglandin-inhibiting  drugs on the  fetal c ardio vascul ar syst em (closure  of the ductus art eriosu s), the use of  keto ro lac t ro met ham ine op htha lm ic  so lut i on during late pregnancy should be avoided.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.3">
                     <id root="fd726133-4709-4ab5-86e6-029c329c3bd7"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>Because many drugs are excreted in human milk, caution should be exercised when ketorolac tromethamine ophthalmic solution is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="b7648788-2568-47f3-ac3e-8a12d36040e1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and efficacy in pediatric patients bel ow t he age of 2 have not been esta blished.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="512c835a-f524-4404-8730-4c2f98056563"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall  clinical  di fferences in  sa fety or  effectiveness have been observed between elderly and other ad ult  patie nts.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="4a0eb3a7-a379-43a6-8866-9464136d0ff3"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph> Keto ro lac t ro met ham ine op htha lm ic  so lut i on 0.5% is a  m ember of the pyrrolo-­pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthal mic use. Its che mical na me is (±)-5-Benzoyl-2, 3-dihydro-1H pyrrolizi ne-1-carboxylic acid co m pound with 2-a mino-2-(hydroxy methyl)-1,3-propanediol ( 1:1) and it has the following structure:</paragraph>
                  <br/>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                     <br/> Keto ro lac t ro met ham ine op htha lm ic  so lut i on is supplied as a sterile isotonic aqueous 0.5% solution, with a pH of 7.4.  Keto ro lac t ro met ham ine op htha lm ic  so lut i on is a race mic  m ixture of R-(+) and S-(-)-  ketor olac tro metha mine. Ketorol ac tro methamine  may exist in t hree  cr ystal  for ms. All  for ms are equally soluble in water. The pKa of ketorolac is 3.5. This white to o ff-white c rystalline su bstance discolors on prolonged exposure to light. The  m o lecular weight of ketorolac tro metha mine is 376.41. The os molality of  keto ro lac t ro met ham ine op htha lm ic  so lut i on is 290  m O s mol/kg.</paragraph>
                  <br/>
                  <paragraph>Each mL of ketorolac tromethamine ophthalmic solution contains: <content styleCode="bold">Active: </content>ketorolac tromethamine USP 0.5%. <content styleCode="bold">Preservative: </content>benzalkonium chloride solution (50%) NF 0.02%. <content styleCode="bold">Inactives: </content>edetate disodium USP 0.1%; octoxynol 40; water for injection USP; sodium chloride USP; hydrochloric acid NF and/or sodium hydroxide NF to adjust the pH.</paragraph>
               </text>
               <effectiveTime value="20181024"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>ketorolac-structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ketorolac-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="23fd5ae5-db01-4359-bcf4-c8fd61f86257"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20181024"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="33b3e967-bb7d-4d51-85f7-0757e544f2c7"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Ketorolac tr o metha mine is a nonsteroidal ant i-inflammatory drug which, when a d ministered syste micall y, has de monstrated anal gesic, a nti-inflam matory, and anti-pyretic activity. The  mechani sm of its action is thought to be due to i ts ability to inhibit prostaglandin biosynthesis.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="bf3100de-9435-4ae8-b748-9811203a7820"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Two drops of 0.5% ketorolac tro metha mine ophthal mic solution instilled into the eyes of patients 12 hours and 1 hour prior to cataract extraction achieved a  mean ketorolac concentration of 95 ng/ mL in the aqueous h u mor of 8 of 9 eyes tested (range 40 to 170 ng/mL).</paragraph>
                        <br/>
                        <br/>
                        <paragraph>One drop of 0.5% ketorolac tro metha mine ophthal mic solution was instilled into 1 eye and 1 drop of vehicle into the other eye TID in 26 healthy subjects. Five (5) of 26 subjects had dete ctable  concent ratio ns of ketorol ac in th eir plas ma (range 11 to 23 ng/mL) at Day 10 during topical ocular treat ment. The range of concent rations following TID dosing of 0.5% ketorolac tro metha mi ne ophthal mic solution are approxi mately 4 to 8% of the steady state  mean  min i m um plas ma concentration observed following four ti mes daily oral a d ministration of 10 mg ketorolac in hu mans (290 ± 70 ng/mL).</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="3be25554-e95d-41e1-a460-337bdf188318"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20181024"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="f413dd9a-4edb-4af4-96e0-93d7be8cf018"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis,Impairment of Fertility</title>
                     <text>
                        <paragraph>Ketorolac tr o metha mine was not ca rcinogenic in either rats given up to 5 mg/kg/day orally for 24 months or in  mice given 2  mg /kg/day orally for 18  months. These doses are approximately 125 ti mes and 50 ti mes higher respectively than the  maxi m um re com mended h u man topical ophthal mic daily dose given as QID for itching to affected eyes on a  mg/kg basis.</paragraph>
                        <paragraph>Ketorolac tromethamine was not mutagenic <content styleCode="italics">in vitro </content>in the Ames assay or in forward mutation assays. Si milarly, it did not result in an <content styleCode="italics">in vitro </content>increase in unscheduled DNA synthesis or an <content styleCode="italics">in vivo </content>i ncrea se in chro moso me breakage in  mice. However, ketorolac trometha mine did result in an increased incide nce in chro mosomal ab err atio ns in Chinese ha mster ovary cells.</paragraph>
                        <br/>
                        <paragraph>Ketorol ac t ro metha mine did not i mpair  fe rtility when ad ministered orally to  male and fe male rats at doses up to 9  mg/kg/day and 16 mg/kg/day, respectively. These doses are respectively 225 and 400 ti mes higher than the typical h u man topical ophthal mic daily dose.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="a90ea477-4583-4b2c-ae05-35c90d3c9320"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph> Two controlled clinical studies sho wed that k etorolac tro metha mine ophthal mic solution was significa ntly  more effective than its  vehicle in relieving ocular itching caused by seasonal all ergic conjuncti vitis.</paragraph>
                  <br/>
                  <paragraph>Two controlled clinical  studies sho wed that  pati ents t reated  for two weeks with ket o rolac tro metha mi ne ophthal mic solution were less likely to have measurable signs of inflammation (cell and flare) than  patients treated with its ve hicle.</paragraph>
                  <br/>
                  <paragraph>Results from clinical studies indicate that k etorolac tro metha mine has no significant effect upon intraocular  pressure; ho wever, chan ges in intraoc ular pressure  may occur following cataract surgery.</paragraph>
               </text>
               <effectiveTime value="20181024"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="482dea95-b37e-4526-b079-161b1c1ebd77"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Ketorolac tromethamine ophthalmic solution 0.5% is supplied sterile in white opaque LDPE dropper bottles with white opaque plug and sealed with gray pantone opaque pilfer-proof caps as follows:</paragraph>
                  <br/>
                  <paragraph>3 mL in 5 mL bottle                                        <content styleCode="bold">NDC </content>47335-219-90</paragraph>
                  <paragraph>5 mL in 5 mL bottle                                        <content styleCode="bold">NDC </content>47335-220-90</paragraph>
                  <paragraph>10 mL in 10 mL bottle                                    <content styleCode="bold">NDC </content>47335-221-90</paragraph>
                  <br/>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Protect from light.</paragraph>
               </text>
               <effectiveTime value="20181024"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="1fe8a5e7-2d54-48f0-a3f4-babbefb97011"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20181024"/>
               <component>
                  <section ID="Section_16.1">
                     <id root="2beaeedb-3de2-4304-b3ed-46dc5a58147c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>17.1 Slow or Delayed Healing</title>
                     <text>
                        <paragraph>Patie nts sh ould be in fo r med of the possibility that slow or delayed healing  may occur while using nonsteroidal anti-inflammatory drugs (NSAIDs).</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.2">
                     <id root="84357767-3db8-40ec-bd67-fd2e8d0278b5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>17.2 Avoiding Contamination of the Product</title>
                     <text>
                        <paragraph>Patie nts sh ould be in str ucted to avoid allow ing the tip of the bottle to co ntact the eye or surrounding structures because this could cause the tip to beco me cont a m inated by common bacteria kn own to cause ocular infections. Serious da mage to the eye and subsequent loss of vision  may result from using contaminated solutions.</paragraph>
                        <br/>
                        <paragraph>Also, to avoid the potential for cross-conta mina tion, the patient should be advised to use one bottle  for e ach eye  foll owing bil ate ral ocular s u rgery. The  use of the s a me bottle of topic al eye drops for both eyes following bilateral ocular surgery is not recom mend ed.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.3">
                     <id root="9c888cfe-d9b5-40db-8696-fcea42d6bbda"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>17.3 Contact Lens Wear</title>
                     <text>
                        <paragraph>Patients should be advised that  keto ro lac t ro met ham ine op htha lm ic  so lut i on should not be ad ministered while wearing contact lenses.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.4">
                     <id root="1065edae-3b18-43e9-ae26-cbb6d16991f3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>17.4 Intercurrent Ocular Conditions</title>
                     <text>
                        <paragraph>Patients should be advised that if they develop an intercurrent ocular condition (e.g., trau ma or infection) or have ocular surgery, they should i mmediately seek their physician’s advice concerning the continued use of  keto ro lac t ro met ham ine op htha lm ic  so lut i on.</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.5">
                     <id root="43b9bb27-7356-4647-a303-00f034e47981"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>17.5 Concomitant Topical Ocular Therapy</title>
                     <text>
                        <br/>
                        <paragraph>Patie nts sh ould be advi sed that if  m ore than one topical op ht hal mic  medication is being used, the  medicines should be ad ministered at least 5  minutes apart.<br/>
                           <br/> Distributed by: <br/>
                           <content styleCode="bold">Sun Pharmaceutical Industries, Inc. <br/>
                           </content>Cranbury, NJ 08512<br/> PJPI0496A<br/> ISS. 07/2017</paragraph>
                     </text>
                     <effectiveTime value="20181024"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_15">
               <id root="fd428ed0-4d36-4a5f-a45c-88e08acc5d16"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -label-3 mL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 47335-219-90 <br/> Ketorolac Tromethamine Ophthalmic Solution <br/> 0.5% <br/> Rx only <br/> 3 mL <br/>
                     </content>
                  </paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20181024"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>spl-Ketorolac-label-3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="spl-Ketorolac-label-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_21">
               <id root="7101c5d5-86ac-4473-9dad-a7aa7722ed30"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -Carton- 3 mL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 47335-219-90 <br/> Ketorolac Tromethamine Ophthalmic Solution <br/> 0.5% <br/> FOR USE IN THE EYES ONLY <br/> Rx only<br/> 3 mL <br/> SUN PHARMA<br/>
                        <br/>
                        <renderMultiMedia referencedObject="MM3"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20181024"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>spl-Ketorolac-carton-1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="spl-Ketorolac-carton-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_24">
               <id root="d21f65ae-c189-4386-80be-bf140c29290d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -Label -5 mL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 47335-220-90 <br/> Ketorolac Tromethamine Ophthalmic Solution <br/> 0.5% <br/> Rx only <br/> 5mL<br/>
                        <br/>
                        <renderMultiMedia referencedObject="MM4"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20181024"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>spl-Ketorolac-label-2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="spl-Ketorolac-label-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_23">
               <id root="ed22e6e3-9cde-4314-94ab-952b65a45685"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -Carton -5 mL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 47335-220-90 <br/> Ketorolac Tromethamine Ophthalmic Solution <br/> 0.5% <br/> FOR USE IN THE EYES ONLY <br/> Rx only <br/> 5 mL <br/> SUN PHARMA<br/>
                        <br/>
                        <renderMultiMedia referencedObject="MM5"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20181024"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>spl-Ketorolac-carton-2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="spl-Ketorolac-carton-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_22">
               <id root="129f108a-111f-40fa-898a-fb88393a2a50"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - Label -10 mL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 47335-221-90<br/> Ketorolac Tromethamine Ophthalmic Solution <br/> 0.5% <br/> Rx only <br/> 10 mL<br/>
                     </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
                  <br/>
               </text>
               <effectiveTime value="20181024"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>spl-Ketorolac-label-1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="spl-Ketorolac-label-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_25">
               <id root="5824b282-a424-4ea0-a801-e1ebf3d23b24"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -Carton -10 mL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 47335-221-90 <br/> Ketorolac Tromethamine Ophthalmic Solution <br/> 0.5% <br/> FOR USE IN THE EYES ONLY <br/> Rx only <br/> 10 mL <br/> SUN PHARMA<br/>
                        <br/>
                        <renderMultiMedia referencedObject="MM7"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20181024"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>spl-Ketorolac-carton-3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="spl-Ketorolac-carton-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>